T-CELL PHENOTYPING SUPPORTS THE USE OF T-CELL ENGAGING ANTIBODIES FOR TREATMENT OF CALRETICULIN MUTATED MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Anna Kuchnio, 419104

HIGH RESOLUTION CHEST COMPUTED TOMOGRAPHY RESPONSES FOR A COHORT OF ADULT WITH PULMONARY LANGERHANS CELL HISTIOCYTOSIS

EHA Library, Long Chang, 419143

SYMPTOM-FOCUSED RESULTS FROM SUMMIT PART 1: AN ONGOING, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL OF BEZUCLASTINIB IN ADULT PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS

EHA Library, Lindsay Rein, 419142

COMPREHENSIVE EVALUATION OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS: FINAL ANALYSIS RESULTS FROM A RANDOMIZED PHASE 3 STUDY

EHA Library, Huafeng Wang, 419141

HIGH RATE OF DISEASE PROGRESSION IN PATIENTS WITH LOW-RISK MYELOFIBROSIS (MF) ENROLLED IN THE PROSPECTIVE MOST STUDY

EHA Library, Michael Grunwald, 419140

INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: PREDICTORS OF RESPONSE AND OUTCOME MAY DRIVE TRANSPLANT DECISION

EHA Library, Francesca Palandri, 419139

FEDRATINIB IN PATIENTS WITH MYELOFIBROSIS EXPOSED TO RUXOLITINIB: AN INDIRECT TREATMENT COMPARISON WITH MOMELOTINIB AND PACRITINIB

EHA Library, Francesca Palandri, 419138

NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN POLYCYTHEMIA VERA (PV): CORRELATION WITH ROPEG-INTERFERON RESPONSE IN LOW PV TRIAL

EHA Library, Tiziano Barbui, 419137

RUXOLITINIB TREATMENT IN PATIENTS WITH POLYCYTHEMIA VERA REDUCES JAK2 ALLELE BURDEN AND IMPROVES HEMATOCRIT CONTROL AND SYMPTOM BURDEN

EHA Library, Claire Harrison, 419136

THE TRIPLE A MODEL-AAA (AGE, ABSOLUTE NEUTROPHIL COUNT, ABSOLUTE LYMPHOCYTE COUNT) PREDICTS SURVIVAL AND THROMBOSIS IN POLYCYTHEMIA VERA

EHA Library, Ivan Krecak, 419135

A REAL-WORLD EVALUATION OF RISK FACTORS FOR DISEASE PROGRESSION IN PATIENTS WITH POLYCYTHEMIA VERA (PV) ENROLLED IN REVEAL

EHA Library, Michael Grunwald, 419134

IMPACT OF CALR MUTATION TYPE AND NON-DRIVER MUTATIONS ON THE RESPONSE TO CYTOREDUCTIVE TREATMENT AND OUTCOMES IN PATIENTS INCLUDED IN THE SPANISH REGISTRY OF ESSENTIAL THROMBOCYTHEMIA (RETE)

EHA Library, Marta Santaliestra Tomas, 419133

ANALYSIS OF CARDIOVASCULAR RISK IN 920 PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS USING NATURAL LANGUAGE PROCESSING

EHA Library, Andrea Duminuco, 419132

THE IMPACT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN 2233 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: RESULTS FROM THE EXPANDED-ACCESS JUMP STUDY

EHA Library, Haifa Kathrin Al-Ali, 419131

RUXOLITINIB STARTING DOSE REDUCTION AFFECT OVERALL SURVIVAL IN MYELOFIBROSIS: AIFA MONITORING REGISTRIES ANALYSIS

EHA Library, Massimo Breccia, 419130

A PHASE 2 STUDY OF PEMIGATINIB (FIGHT-203; INCB054828) IN PATIENTS WITH MYELOID/LYMPHOID NEOPLASMS WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 GENE REARRANGEMENT

EHA Library, Alessandro Vannucchi, 419129

REVISED “IRR6” MODEL IN INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB

EHA Library, Francesca Palandri, 419128

CALRETICULIN MUTATIONS INFLUENCE RESPONSE AND OUTCOME IN TRANSPLANT-AGE MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB

EHA Library, Francesca Palandri, 419127

LONG TERM FOLLOW-UP RESULTS OF PHASE II CLINICAL TRIAL EVALUATING RUXOLITINIB (RUX) AND AZACITIDINE (AZA) COMBINATION THERAPY IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

EHA Library, Sankalp Arora, 419126

REAL-WORLD DATA ON DIRECT ORAL ANTICOAGULANTS IN BCR::ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: A MULTICENTER STUDY ON BEHALF OF SUBCOMMITTEE ON MPNS FOR TURKISH SOCIETY OF HEMATOLOGY

EHA Library, Mehmet Baysal, 419125

EFFICACY OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS WHO HAVE OVERLAPPING THROMBOCYTOPENIA AND ANEMIA

EHA Library, Pankit Vachhani, 419124

AGE-DEPENDENT LINK BETWEEN ARTERIAL THROMBOSIS AND SECONDARY CANCER IN PH-NEG MPN: CASE-CONTROL STUDY INSIGHTS

EHA Library, Tiziano Barbui, 419123

DECIPHERING THE PREDICTORS OF DEATH IN POLYCYTHEMIA VERA: FOCUS ON THE NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) AND THE INCIDENCE OF ARTERIAL THROMBOSIS

EHA Library, Tiziano Barbui, 419122

PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND HEALTH OUTCOMES IN A REAL-WORLD POPULATION OF PATIENTS WITH MYELOFIBROSIS TREATED WITH FEDRATINIB

EHA Library, Francesco Passamonti, 419121

IMPACT OF TP53 MUTATION ALLELIC BURDEN ON OUTCOME OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: A STUDY FROM COMMAND CONSORTIUM.

EHA Library, Talha Badar, 419120

THROMBOSIS RATES FOR MPN PATIENTS BY ATTAINED AGE AND TIME SINCE DIAGNOSIS: A SWEDISH REGISTER-BASED MATCHED-COHORT STUDY

EHA Library, Nurgul Batyrbekova, 419119

UNVEILING THE EFFECTIVENESS AND PREDICTIVE FACTORS OF JAKTINIB TREATMENT IN MYELOFIBROSIS PATIENTS WITH ANEMIA

EHA Library, Huafeng Wang, 419118

PROGRESSION TO MYELOFIBROSIS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: AN ANALYSIS FROM THE PROSPECTIVE MOST STUDY

EHA Library, Ruben Mesa, 419117

CALRETICULIN AND JAK2V617F DRIVER MUTATIONS INDUCE DISTINCT MITOTIC DEFECTS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Daniel Moreno-Andrés, 419116

PRECLINICAL EVALUATION OF INCB160058 - A NOVEL AND POTENTIALLY DISEASE-MODIFYING THERAPY FOR JAK2V617F MUTANT MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Hamza Celik, 419115

MUTATIONAL LANDSCAPE OF PATIENTS ENROLLED IN THE LOW-PV TRIAL WITH ROPEGINTERFERON ALFA-2B

EHA Library, Paola Guglielmelli, 419114

DUPLICATION OF CHROMOSOME 9P INDUCES T CELL EXHAUSTION AND INCREASED CLONOGENICITY OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN JAK2-MUTANT MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Ruggiero Norfo, 419113

HUMANIZED IMMUNOCOMPETENT MOUSE MODEL FOR THE PRECLINICAL THERAPEUTIC EVALUATION OF T CELL ENGAGING BISPECIFIC ANTIBODIES TARGETING CALRETICULIN MUTANT MPN

EHA Library, Shengen Xiong, 419112

MIR-93 ATTENUATES CALR MUTANT-DRIVEN ONCOGENIC ACTIVITY IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Chih-Cheng Chen, 419111

EXPRESSION OF GERMLINE JAK2 R1063H REPRESENTS INCREASED RISK OF THROMBOSIS AND IMPAIRS NORMAL HEMATOPOIETIC DEVELOPMENT IN MICE

EHA Library, Veronika Zimolova, 419110

INFLAMMATION NOT HAEMATOPOIESIS CAUSES SPLENOMEGALY IN A MOUSE MODEL OF POLYCYTHAEMIA VERA.

EHA Library, Cavan Bennett, 419109

EFFECT OF NOVEL AGENTS ON THE MECHANISM OF FIBROCYTE-MEDIATED INDUCTION OF MYELOFIBROSIS

EHA Library, Takaaki Maekawa, 419108

FEDRATINIB INHIBITS IMMUNE EVASION AND RESTORES B CELL MATURATION: BIOMARKER ANALYSIS FROM THE FREEDOM2 STUDY

EHA Library, Claire Harrison, 419107

ALK2 AND JAK2 INHIBITION FOR IMPROVED TREATMENT OF ANEMIA IN MYELOFIBROSIS PATIENTS: PRECLINICAL PROFILE OF AN ALK2 INHIBITOR ZILURGISERTIB IN COMBINATION WITH RUXOLITINIB

EHA Library, Ricardo Macarron, 419106

CDK8/19 INHIBITION: A PROMISING THERAPEUTIC STRATEGY IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Zachary Zaroogian, 419105

IMMUNOPHENOTYPIC ANALYSIS OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS RECEIVING THERAPY WITH THE BET INHIBITOR PELABRESIB

EHA Library, Rosa Andres Ejarque, 419103

COMPLEX ALTERNATIVE SPLICING AND RELATED NEOANTIGEN PATTERNS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Jing Sun, 419102

ESTABLISHMENT OF A NOVEL PRECLINICAL MOUSE MODEL FOR ADVANCED SYSTEMIC MASTOCYTOSIS

EHA Library, Martina Konantz, 419097

IMPACT OF GENETIC BACKGROUND ON THE FIBROTIC TRANSFORMATION IN MURINE MPN-MODELS

EHA Library, Yu-An Lin, 419098

REAL WORLD PRACTICE REVEALS SERUM TNFΑ AS THE EARLY PROGNOSTIC PREDICTOR FOR MYELOFIBROSIS WITH RUXOLITINIB TREATMENT

EHA Library, Xinjie Chen, 419099

RKER-050, A MODIFIED ACTIVIN RECEPTOR TYPE IIA LIGAND TRAP, RESCUED ANEMIA AND INCREASED MUSCLE MASS AND STRENGTH IN A MOUSE MODEL OF MYELOFIBROSIS

EHA Library, Blake Moses, 419100

MONOCYTES WITH HIGHER EXPRESSION OF CD38 ACCELERATE MYELOFIBROSIS IN MPN

EHA Library, yiru yan, 419101

T-cell engaging immunotherapy in early treatment of B-cell acute lymphoblastic leukemia (B-ALL)

EHA Library, Amgen, 4144088

How to Make the Most out of a Rapidly Evolving Treatment Landscape: Bispecific Antibodies in Relapsed Refractory Multiple Myeloma (RRMM)

EHA Library, Pfizer, 4144087

VITAMIN C SUPPLEMENTATION IN PATIENTS WITH CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE OR LOW-RISK MYELOID MALIGNANCIES: RESULTS FROM EVI-2, A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2 STUDY

EHA Library, Stine Ulrik Mikkelsen, 4136519

ELEVATED HEMOGLOBIN OF ANDEAN AYMARAS IS CAUSED BY ALTERNATIVELY SPLICED NFKB1

EHA Library, Josef Prchal, 4136518

ELA026 TARGETING OF SIRP(+) IMMUNE CELLS RESULTS IN A HIGH RESPONSE RATE AND IMPROVED 2-MONTH SURVIVAL OF TREATMENT-NAIVE MALIGNANCY-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PHASE 1 STUDY

EHA Library, Abhishek Maiti, 4136517

GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (GLOFIT-GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS OF A GLOBAL RANDOMIZED PHASE III TRIAL (STARGLO)

EHA Library, Jeremy Abramson, 4136516

ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN UNTREATED MANTLE CELL LYMPHOMA: RESULTS FROM THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED ECHO TRIAL

EHA Library, Michael Wang, 4136515

INTRA- AND EXTRACELLULAR PROTEOME DYNAMICS DURING NORMAL AND MALIGNANT HEMATOPOIETIC STEM CELL EXPANSION

EHA Library, Maria Jassinskaja, 4136514

RESULTS FROM THE RANDOMIZED PHASE 3 DREAMM-8 STUDY OF BELANTAMAB MAFODOTIN PLUS POMALIDOMIDE AND DEXAMETHASONE VS POMALIDOMIDE PLUS BORTEZOMIB AND DEXAMETHASONE IN REPALPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Meletios Dimopoulos, 4136513

Abstract Book 2024

EHA Library, Faculty / Presenters, 422826

Education Session on Myelodysplastic syndromes (MDS)

EHA Library, Faculty / Presenters, 402946

Education Session on Immunotherapy in indolent lymphomas

EHA Library, Faculty / Presenters, 402950

Education Session on What's new in myeloproliferative neoplasms (MPN)?

EHA Library, Faculty / Presenters, 402945

Education Session on What is hot in hemophilia?

EHA Library, Faculty / Presenters, 402944

Education Session on Pediatric acute myeloid leukemia (AML)

EHA Library, Faculty / Presenters, 402937

Education Session on Novel therapeutic approaches in acute myeloid leukemia (AML)

EHA Library, Faculty / Presenters, 402936

Education Session on Novel agents in multiple myeloma

EHA Library, Faculty / Presenters, 402933

Education Session on Inherited red blood cell disorders

EHA Library, Faculty / Presenters, 402932

Education Session on Hemochromatosis: From novel classification to treatment guidelines

EHA Library, Faculty / Presenters, 402929

Education Session on Hematopoietic stem cell biology and transplantation

EHA Library, Faculty / Presenters, 402928

Education Session on Genetics across all lymphoid malignancies

EHA Library, Faculty / Presenters, 402927

Education Session on Fetal-neonatal cytopenias: Focus on anemia

EHA Library, Faculty / Presenters, 402926

Education Sessions on Diffuse Large B-cell Lymphoma (DLBCL)

EHA Library, Faculty / Presenters, 402925

Education Sessions on CNS-involvement in acute lymphoblastic leukemia (ALL)

EHA Library, Faculty / Presenters, 402769

Education Sessions on Chronic myeloid leukemia (CML)

EHA Library, Faculty / Presenters, 402755

Education Session on Chronic lymphocytic leukemia (CLL)

EHA Library, Faculty / Presenters, 402754

Education session on Acute chest syndrome in sickle cell disease

EHA Library, Faculty / Presenters, 402753

Presidential Session II

EHA Library, Faculty / Presenters, 402752

Presidential Session I & Awards

EHA Library, Faculty / Presenters, 402751

Education Session on Acute acquired thrombosis and hemostasis challenges

EHA Library, Faculty / Presenters, 402750

TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING LUSPATERCEPT IN ROUTINE CLINICAL PRACTICE IN THE UNITED STATES

EHA Library, Sudipto Mukherjee, 386562

LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY

EHA Library, Uwe Platzbecker, 386522

LONG-TERM SAFETY WITH ≥12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES

EHA Library, Wojciech Jurczak, 386447

IMPLICATIONS OF REGISTRY DATA FOR ACUTE MYELOID LEUKEMIA (AML) TREATMENT AND CARE DURING THE COVID-19 PANDEMIC

EHA Library, Bart Scott, 386418

PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA

EHA Library, Shaun Fleming, 386396

SURVIVAL OUTCOMES WITH CPX-351 VS 7+3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY

EHA Library, Jorge Cortes, 386346

CARDIOTOXICITY OF CPX-351 VS 7+3 IN PATIENTS WITH UNTREATED HIGH-RISK ACUTE MYELOID LEUKEMIA

EHA Library, Jorge Cortes, 386345

A REAL-WORLD EVALUATION OF TREATMENT PATTERNS AND OUTCOMES OF ACUTE MYELOID LEUKEMIA INDUCTION THERAPIES IN THE COMMUNITY SETTING

EHA Library, Keri Maher, 386344

A FIRST-IN-HUMAN STUDY OF CD123 NK CELL ENGAGER SAR443579 IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR HIGH RISK-MYELODYSPLASIA

EHA Library, Anthony Selwyn Stein, 386323

FIVE-YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DLBCL: FINAL RESULTS FROM THE PHASE II L-MIND STUDY

EHA Library, Johannes Duell, 385588

SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL

EHA Library, Tycel Phillips, 385544

PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH >3 YEARS FOLLOW-UP FROM START OF ENROLLMENT

EHA Library, Wojciech Jurczak, 385537

BASELINE AND EARLY POST-INFUSION BIOMARKERS ASSOCIATED WITH OPTIMAL RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL) IN THE KARMMA-3 STUDY OF TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA

EHA Library, Marc S. Raab, 386630

BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE-CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS

EHA Library, Yi Lin, 386638

A PHASE 1 STUDY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF DREAMM-9

EHA Library, Saad Z. Usmani, 386693

BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD OBSERVATIONAL STUDY UPDATE

EHA Library, Michel Delforge, 387224

LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY

EHA Library, Matteo Giovanni Della Porta, 387802

EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY

EHA Library, Francesco Passamonti, 387867

PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY

EHA Library, Francesco Passamonti, 387868

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3)

EHA Library, Meletios Dimopoulos, 387899

HIGH COMPLETE RESPONSE RATE WITH TNB-486, A NOVEL CD19XCD3 T-CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY

EHA Library, Ryan Jacobs, 387924

INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Francesca Palandri, 385512